Guidelines on Germline Testing for Urologic Tumor Syndromes.
Patrick T Gomella1, James Ryan Mark1, Veda N Giri2
1Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
European Urology Focus
|July 8, 2022
Summary
Genetic testing for inherited mutations is crucial for diagnosing urologic tumor syndromes. Understanding germline testing guidelines impacts patient and family screening and treatment decisions.
Area of Science:
- Urologic oncology
- Medical genetics
- Precision medicine
Background:
- Increasing use of genetic testing in patient care.
- Association of inherited gene mutations with multiple urologic cancers.
- Impact of germline mutations on patient and family screening and treatment.
Framework:
- Guidelines for germline testing in suspected urologic tumor syndromes.
- Focus on inherited genetic mutations impacting genitourinary cancers.
Implementation:
- Summarizing current germline testing guidelines.
- Providing information for healthcare providers.
Implications:
- Informed screening and treatment decisions for patients.
- Risk assessment and management for at-risk family members.
- Advancing precision medicine in urologic oncology.
